# 2019

# Reaxys – Greek project: Engaging activity



Juan Pablo Aita Vassallo

#### Introduction:

It's our mission at Elsevier to advance science by serving the researcher community. It is our commitment engaging with selected chemical societies around the world, with the aim to uncover future areas of collaboration in science through information and data analytics. Hence, Elsevier would like to offer a full engaging activity with Reaxys and Reaxys Medicinal Chemistry databases to Greek universities.

The project, as explained below, is based on the feedback derived during the recent meeting between Elsevier and some of the members of Heal Link Serials Committee in Crete.

Elsevier understands that the decision of using the right database in the chemistry community is extremely important for Greece. Not only this choice will impact the future of the next generation of young chemistry students, but it will also play a key role in a country level strategy that will lead to a better quality of the chemistry research performance in Greece. Hence, the aim of this initiative is to further explore Reaxys and Reaxys Medicinal Chemistry in a group of universities from Greece. Therefore, Elsevier would like to offer a six months free access to both data bases in order to engage with the below mentioned universities in Greece.

- Aristotle university of Thessaloniki.
- National & Kapodistrian university of Athens.
- Hellenic open university.
- National Technical university of Athens.
- Technical university of Crete.
- University of Patras.
- University of Ioannina.
- University of Crete.

The approach and benefits of this project are explained below:

## 1. The approach:

Elsevier will enable free access to Reaxys and Reaxys Medicinal Chemistry during six months to some universities in Greece. During the engaging activity, we will actively monitor and collect feedback and the statistic usage of these group of universities. By exploring this data, universities will have more evidence to make their final decision, to acquire Reaxys via a national level agreement.

From December 2019 onwards, Elsevier will engage with professors, students and librarians in the chemistry faculties. The goal of the project is to allow all universities in Greece to test Reaxys for a longer period assessing the potential value of Reaxys in order to decide whether a subscription to Reaxys — Reaxys Medicinal Chemistry is desirable for their institution.

January 1, 2019

#### 2. Timeline and activities of this program:

From the 2<sup>nd</sup> of December 2019 until the 31<sup>th</sup> of May 2020.

# Elsevier activities with Reaxys and RMC:

- **Kick-off Reaxys program:** On the 4<sup>th</sup> and 5<sup>th</sup> of December 2019, Elsevier will offer a Reaxys and Reaxys Medicinal chemistry online webinar to introduce both databases.
- **Demo on Campus:** From the 13<sup>th</sup> until the 17<sup>th</sup> of January. During this week an Elsevier representative will visit each of the universities joining this program in order to teach their users how to use Reaxys.

After these two activities, (on the first week of March). Elsevier will collect usage and feedback to evaluate if there is engagement from universities towards our Reaxys product. Elsevier may decide to interrupt access to both data bases in case the usage statistic and engagement are low at the end of the onboarding period.

- Last webinar: During April (dates to be defined), Elsevier will offer the final Reaxys and Reaxys Medicinal chemistry online webinar.

#### 3. Global Benefits:

These are some of the benefits that Elsevier and Greek universities can obtain by joining this project/engagement activity:

- Full understanding of Reaxys and RMC value in those universities where we trialed Reaxys.
- Obtain a better understanding of the specific institutional needs towards the use of the right database by using Reaxys.
- The inclusion of an engagement program for researchers from universities joining the trial (online webinars and demos on campus). This program will also include engaging with librarians at each institution
- Reaxys will contribute to enrichment of the quality of the research in Greece. (during those months of trial)

#### 4. Product benefits:

Reaxys is designed to meet the demand for rapid access to relevant literature, including peer-reviewed articles and patents, experimental procedures, and substance property and reaction data.

- Students and professors will have unlimited access to Reaxys and Reaxys Medicinal Chemistry from their institutions in Greece.
- Access to accurate substance synthesis pathways with integrated links to public and proprietary databases of substance availability.
- Time saved/efficiency obtained in their current reaction search workflow.
- Access to workflows designed for use in classrooms with undergraduates and post-graduates.

January 1, 2019

### Reaxys is proven to:

- Empower confident and thorough investigation of research topics.
- Help users to find answers more quickly than with other chemistry research solutions.
- Enable greater discovery from a broader range of content.
- Empower all users, regardless of research experience
- Offer additional support for students and other first-time users

#### Reaxys Medicinal Chemistry, key benefits:

- Confident assessment of compound effects on target proteins
- Quantification of compound and target affinities.
- Rapid assessment of large hit sets.
- Direct data use without need for normalization.
- Excellent overviews of the research environment

#### Content and discoverability:

Reaxys uniquely provides access to multiple resources through a single user interface:

- High-quality peer-reviewed literature from a wide range of chemistry and chemical sciences journals, include prestigious society journals
- Patents from the World, EU, US, Japan, South Korea, China and Taiwan offices
- Substance databases with availability information and/or experimental data, including eMolecules, ACD Labs, the Sigma-Aldrich database and WuXi AppTech's LabNetwork

#### RMC content includes:

- Structure—activity relationship (SAR) profiles
- Data from in vivo animal studies
- In vitro efficacy, pharmacokinetic, toxicity and safety data
- In vitro metabolic profiles

#### User experience

The Reaxys user interface has received much positive feedback, with scientists stating that they like:

- The easy-to-read results screens.
- The intuitive Quick Search and Query Builder functions.
- The ease of navigation between result types.

Juan Pablo Aita Vassallo January 1, 2019

Reaxys is a fully integrated research solution that enables all users, from beginners to highly experienced researchers, to use the full extent of the functionality, thus improving usage and supporting research and education goals.

Reaxys allows users to export results in multiple formats and save searches.

# **Database**

The ongoing indexing and excerption of patent content from Asian offices makes Reaxys an incredibly important resource to support competitive R&D: only 2% of patents from Asian offices appear in the WO patents, while the patent content represents over 50% of world output.

The integration of the Sigma-Aldrich, LabNetwork, ACD Labs, eMolecules and CambridgeSoft ACX databases is unique and highly valuable. Users can check compound details from all those sources within a single search session without having to perform multiple, time-consuming searches.

Discovery of synthesis pathways is facilitated by the synthesis pathway generation feature, which enables quick comparisons of options and conditions, supporting synthesis-or-purchase decisions.

The range of content used as a source of Index Terms and compounds ensures comprehensive coverage of literature and structure-searchable compounds. Deep manual indexing and excerption of compound data from the core chemistry journals successfully runs alongside rules-based automated content enrichment for the comprehensive collection of chemistry-related periodicals, ensuring that every search retrieves information from the broadest set of content.

Juan Pablo Aita Vassallo

Solution Sales Manager,

ELSEVIER | Life Sciences

j.vassallo.1@elsevier.com

t +31 623 50 56 44

Radarweg 29 1043 NX Amsterdam, The Netherlands

January 1, 2019